Abiomed
Stock
Stock
ISIN: US0036541003
Ticker: ABMD-RM
US0036541003
ABMD-RM
Price
Price
CHART BY
Frequently asked questions
What are the analyst ratings and target price for Abiomed's stock?
Currently, 1 analysts cover Abiomed's stock, with a consensus target price of $300.00. Analyst ratings provide insights into the stock's expected performance.
What is Abiomed's revenue over the trailing twelve months?
Over the trailing twelve months, Abiomed reported a revenue of $1.07B.
What is the EBITDA for Abiomed?
Abiomed's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $274.18M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Abiomed?
Abiomed has a free cash flow of $217.22M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Abiomed have, and what sector and industry does it belong to?
Abiomed employs approximately 2,003 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
Financials
- Revenue (TTM)
- $1.07B
- EBITDA (TTM)
- $274.18M
- Free Cashflow (TTM)
- $217.22M
Analyst Ratings
The price target is $300.00 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA.
- Employees
- 2,003
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- ISIN
- US0036541003
- Primary Ticker
- ABMD-RM
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet